Osobennosti funktsional'nogo sostoyaniyakory nadpochechnikov i shchitovidnoy zhelezypri metabolicheskom sindrome

Cover Page

Abstract


The aim. To study the functional state of adrenal cortex and thyroid gland in metabolic syndrome (MS). 186 women and 65 men
were included. Blood levels of cortisol, dehydroepiandrosterone sulphate, total thyroxin, total triiodothyronine, thyroid stimulating
hormone were studied in subjects with and without metabolic syndrome (IDF test) and their relation with MS components. The results.
75 (29,9%) of the 251 examined patients had MS. In the group with MS the levels of total thyroxin and dehydroepiandrosterone
sulphate were decreased to 1,90±0,18 microgram/milliliter vs. 2,37±0,12 microgram/milliliter (р=0,033) in patients without MS and
2,19±0,26 nmol/l vs. 2,59±0,15 nmol/l (р=0,040), respectively. The levels of dehydroepiandrosterone sulphate were inversely correlated
with the systolic blood pressure (r=-0,23, р<0,001), high density lipoprotein (r=-0,22, p=0,001), triglycerides (r=-0,14, p=0,034),
C-peptide (r=-0,44, p<0,001). The total thyroxin content was inversely correlated with low density lipoprotein (r=-0,38, р=0,026).
The patients with low dehydroepiandrosterone sulphate had higher rate of MS components. The coefficient of association between low
dehydroepiandrosterone of sulphate and MS existence was +0,39 (р=0,009). There wasnt any difference between the group with MS
and without in the level of morning cortisol in blood and after the 1 mg dexamethasone test. Conclusion. MS formation is associated with
the reduction of the levels of dehydroepiandrosterone sulphate and total thyroxin in blood, the levels of which are inversely correlated
with the elements of MS. The content of dehydroepiandrosterone sulphate in blood can be one of the indices of metabolic «wellbeing».

  1. ВНОК. Диагностика и лечение метаболического синдрома. Российские рекомендации. - М., 2007. - 4 с.
  2. Гончаров Н.П., Кация г.В., Нижник А.Н. Формула жизни. Дегидроэпиандростерон: свойства, метаболизм, биологическое значение. - М.: ООО «Издательское товарищество «Адамантъ»», 2004. - 159 с.
  3. Гончаров Н.П., Кация г.В., Нижник А.Н. Дегидроэпиандростерон и функции мозга // Вестник Российской АМН. - 2006. - № 6:. - С. 45-50.
  4. Гублер Е.В. Информатика в патологии, клинической медицине и педиатрии. / Е.В. Гублер. - Л.: Медицина, 1990. - 176 с.
  5. Каминский Л.С. Статистическая обработка лабораторных и клинических данных. / Л.С. Каминский. - Л.: Медицина, 1964. -251 с. 6. Ожирение: этиология, патогенез, клинические аспекты / под ред.
  6. И.И. Дедова, г.А. Мельниченко. - М.: Медицинское информационное агентство, 2004. - 456 с.
  7. Соколов Е.И., Миронова Е.К., Зыкова А.А. Гормональная дезинтеграция При метаболическом синдроме // Клиническая медицина. - 2008. - № 2. - С. 52-56.
  8. Терещенко И.А. Трудности и ошибки При оценке тиреоидного ста- туса // Медицинская газета. - 2000. - 80 с.
  9. Чазова Е.И., Мычка В.Б. Метаболический синдром. - М.: Медиа Медика, 2008. - С. 7-8.
  10. Юнкеров В.И., Григорьев С.Г. Математико-статистическая обработка данных медицинских исследований. СПб.: ВМедА, 2002. - 266 с.
  11. Barclay L. Medscape Medical News. New definition of the metabolic syndrome: a newsmaker interview with Sir George Alberti, MA, DPbil, BMBCb. Available at: http: www.medscape.com/viewarticle/504382 Accessed July 8, 2005.
  12. Björntorp P., Holm J., Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus // Diab Med. - 1999. - № 16. - Р. 373-383.
  13. Coleman D., Leiter E., Applezweig N. Therapeutic effects of DHA metabolites in diabetic mutant mice // Endocrinology. - 1984. - № 115. - С. 229-246.
  14. Hak A.E., Witteman J.C., de Jong F.H. et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study // J Clin Endocrinol Metab. - 2002. - № 87(8). - Р. 3632-3639.
  15. Hampl R., Morfin R., Starka L. Minirewiew. 7-hydroxylated derivatives of dehydroepiandrosterone : what are they godd for? // Endocrin. Regul. - 1997. - № 31 (4). - Р. 211-218.
  16. Herrington D. Dehydroepiandrosterone and coronary atherosclerosis // Ann N Y Acad Sci. - 1995. - № 774. - Р. 271-280.
  17. Meyer K., Deutscher J., Anil M. et al. Serum androgen levels in adolescents with type 1 diabetes: relationship to pubertal stage and metabolic control // J Endocrinol Invest. - 2000. - № 23 (6). - Р. 362-368.
  18. Morales A.J., Nolan J.J., Nelson J.S., Yen S.S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age // J. Clin. Endocrinol. - 1994. - № 78 (6). - Р. 1360-1367.
  19. Muller S., Cleary M. Glucose metabolism in isolated adipocytes from lean and obese Zucker rats following treatment with DHA // Metab Clin Exp. - 1985. - № 34. - Р. 278-284.
  20. Rosmond R., Dallman M., Björntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and haemodynamic abnormalities // J. Clin. Endocrinol Metab. - 1998. - № 83. - Р. 1853-1859.
  21. Tchernof A., Deaspers A.S., Belanger A. et al. Reduced testosterone and adrenal C19 steroid levels in obese men // Metabolism. - 1995. - № 44 (4). - 513-519.

Views

Abstract - 750

PDF (Russian) - 367

Cited-By


Dimensions


Copyright (c) 2011 Madyanov I.V., Kichigin V.A., Markova T.N., Semakina S.M., Bashkova I.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies